Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers incl... Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions. 더 보기
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of...
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
Anticipates multiple clinical updates in the next 12-18 months, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of one new asset based on its...
SEATTLE, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.37 | -9.68586387435 | 3.82 | 3.91 | 3.2206 | 584111 | 3.44589275 | CS |
4 | -0.03 | -0.862068965517 | 3.48 | 4.24 | 3.02 | 1012464 | 3.52590472 | CS |
12 | -5.48 | -61.366181411 | 8.93 | 8.93 | 2.7 | 1684379 | 3.70994262 | CS |
26 | -9.23 | -72.7917981073 | 12.68 | 16.55 | 2.7 | 1188582 | 7.3565083 | CS |
52 | -5.269 | -60.4312421149 | 8.719 | 19.05 | 2.7 | 2517750 | 12.21416991 | CS |
156 | -0.313 | -8.31783151741 | 3.763 | 19.05 | 2.05 | 1702953 | 10.42524389 | CS |
260 | -0.313 | -8.31783151741 | 3.763 | 19.05 | 2.05 | 1702953 | 10.42524389 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관